AVDL - Avadel Pharmaceuticals Sees Robust Uptake For Its Newly Approved Sleep Disorder Drug | Benzinga
Avadel Pharmaceuticals plc (NASDAQ: AVDL) recognized $7.0 million in net product revenue for Q3. Net product revenue consists of Lumryz product sales, launched in the U.S. in June. Analysts estimated revenues of $5.09 million.
In May, the FDA granted final approval to Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for cataplexy or excessive daytime sleepiness (EDS) in ...